Advertisement

Tumor Microvasculature as a Therapeutic Target During Radiotherapy

  • Dennis E. Hallahan
  • Don Stacy
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The controversy surrounding the use of antiangiogenic agents during radiotherapy is based upon the concern that the resulting hypoxia will impair tumor response to radiation (1). Tumor hypoxia is a therapeutic problem, as it makes solid tumors resistant to sparsely ionizing radiation and some forms of chemotherapy. Hypoxia also may increase the percentage of tumor cells in G1, resulting in greater resistance to therapy. Recent clinical studies suggest hypoxia can enhance malignant progression and increase aggressiveness through clonal selection and genome changes. In addition, hypoxia is an independent prognostic factor in cervix cancers, carcinomas of the head and neck, and soft-tissue sarcomas. Despite these concerns, recent preclinical studies have suggested that antiangiogenic agents enhance tumor control in response to fractionated irradiation.

Keywords

Vascular Endothelial Growth Factor Ionize Radiation Radiat Oncol Biol Phys Tumor Blood Tumor Blood Vessel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28 (2 Suppl 8): 29–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Song C, Payne JT, Levitt SH. Vascularity and blood flow in x-irradiated Walker carcinoma 256 of rats. Radiology 1972; 104: 693–697.PubMedGoogle Scholar
  3. 3.
    Song C, Sung JH, Clement JJ, et al. Vascular changes in neuroblastoma of mice following X-irradiation. Cancer Res 1974; 34: 2344–2350.PubMedGoogle Scholar
  4. 4.
    Ting LL. Sarcoma blood perfusion change after x-irradiation. Int J Radiat Oncol Biol Phys 1991; 60: 335–339.Google Scholar
  5. 5.
    Yamaura H, Yamada K, Matsuzawa T. Radiation effect on the proliferating capillaries in rat transparent chambers. Int J Radiat Oncol Biol Phys 1976; 30: 179–187.Google Scholar
  6. 6.
    Kallman R,DeNardo GL, Stasch MJ. Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res 1972; 32: 483–490.PubMedGoogle Scholar
  7. 7.
    Hilmas D, Gillette EL. Microvasculature of C3H/Bi mouse mammary tumors after x-irradiation. Radiat Res 1975; 61: 128–143.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson R. A thermodynamic method for investigation of radiation-induced changes in the microcirculation of human tumors. Int J Radiat Oncol Biol Phys 1976; l:659–670.PubMedCrossRefGoogle Scholar
  9. 9.
    Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374–3378.PubMedGoogle Scholar
  10. 10.
    Fleischer AC. Sonographic depiction of tumor vascularity and flow. J Ultrasound Med 1999; 19: 55–61.Google Scholar
  11. 11.
    Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9 (1): 49–58.PubMedGoogle Scholar
  12. 12.
    Hallahan DE, Staba-Hogan MJ, Virudachalam S, et al. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res 1998; 58 (22): 5216–5220.PubMedGoogle Scholar
  13. 13.
    Hallahan DE, Virudachalam S. Accumulation of P-selectin in the lumen of irradiated blood vessels. Radiat Res 1999; 152 (1): 6–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Lencioni R, Pinto F, Armillotta N, Bartolozzi C. Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 1996; 201: 353–358.PubMedGoogle Scholar
  15. 15.
    Choi B, Kim TK, Han JK, et al. Power versus conventional color Doppler sonography: comparison in the depiction of vasculature in liver tumors. Radiology 1996; 200: 55–58.PubMedGoogle Scholar
  16. 16.
    Bartolozzi C, Lencioni R, Paolicchi A, et al. Differentiation of hepatocellular adenoma and focal nodular hyperplasia of the liver: comparison of power Doppler imaging and conventional color Doppler sonography. Eur Radiol 1997; 7: 1410–1415.PubMedCrossRefGoogle Scholar
  17. 17.
    Hosoki T, Mitomo M, Chor S, et al. Visualization of tumor vessels in hepatocellular carcinoma: power Doppler compared with color Doppler and angiography. Acta Radiol 1997; 38: 422–427.PubMedGoogle Scholar
  18. 18.
    Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS 174T. Cancer Res 1992; 52: 6553–6560.PubMedGoogle Scholar
  19. 19.
    Fuks Z. Intravenous bFGF protects the lung against radiation-induced apoptosis in vivo. Cancer J 1995; 1: 62–72.Google Scholar
  20. 20.
    Valter MM, Hugel A, Huang HJ, et al. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 1999; 59 (21): 5608–5614.PubMedGoogle Scholar
  21. 21.
    Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59 (20): 5209–5218.PubMedGoogle Scholar
  22. 22.
    Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166–2174.PubMedGoogle Scholar
  23. 23.
    Zhu Z, Lu D, Kotanides H, et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase domain-containing receptor antibody. Cancer Lett 1999; 1 (136): 203.CrossRefGoogle Scholar
  24. 24.
    Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Research 2000; 60 (19): 5565–5570.PubMedGoogle Scholar
  25. 25.
    Goldman C, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci 1998; 95: 8795–8800.PubMedCrossRefGoogle Scholar
  26. 26.
    Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 1993; 90(22):10,705–10,709.CrossRefGoogle Scholar
  27. 27.
    Seko Y, Takahashi N, Tobe K, et al. Vascular endothelilal growth factor (BEGF) activates Raf-1 mitogenactivated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. J Cell Physiol 1998; 3: 239–246.CrossRefGoogle Scholar
  28. 28.
    Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61: 39–44.PubMedGoogle Scholar
  29. 29.
    Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 1998; 273(46):30,336–30,343.CrossRefGoogle Scholar
  30. 30.
    Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98(2):147–157.CrossRefGoogle Scholar
  31. 31.
    Fugio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999; 274(23):16,349–16,354.Google Scholar
  32. 32.
    Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72 (6): 835–846.PubMedCrossRefGoogle Scholar
  33. 33.
    Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt 1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269(43): 26,988–26,995.Google Scholar
  34. 34.
    Fong TL, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the VEGF receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99–106.PubMedGoogle Scholar
  35. 35.
    Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59 (21): 5412–5416.PubMedGoogle Scholar
  36. 36.
    Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1 (1): 31–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Nor JE, Christensen J, Mooney DJ, Polverini Pi. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154 (2): 375–384.PubMedCrossRefGoogle Scholar
  38. 38.
    Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins surviving and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264 (3): 781–788.PubMedCrossRefGoogle Scholar
  39. 39.
    Zundel W, Giaccia A, et al. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dey 1998; 12 (13): 1941–1946.CrossRefGoogle Scholar
  40. 40.
    Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a Bad influence. Cell 1996; 87 (4): 589–592.PubMedCrossRefGoogle Scholar
  41. 41.
    Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14–3–3 not Bc1–X(L). Cell 1996; 87 (4): 619 – 628.PubMedCrossRefGoogle Scholar
  42. 42.
    Yaffe MB, Rittenger K, Volinia S, et al. The structural basis for 14–3–3:phosphopeptide binding specificity. Cell 1997; 91 (7): 961 – 971.PubMedCrossRefGoogle Scholar
  43. 43.
    Burgering BM, Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376 (6541): 599–602.PubMedCrossRefGoogle Scholar
  44. 44.
    Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81 (5): 727–736.PubMedCrossRefGoogle Scholar
  45. 45.
    Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 1996; 271(36):21,920–21,926.Google Scholar
  46. 46.
    Klippel A, Reinhard C, Kavanaugh WM, et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996; 16 (8): 4117–4127.PubMedGoogle Scholar
  47. 47.
    Takeuchi H, Kanematsu T, Misumi Y, et al. Distinct specificity in the binding of inositol phosphates by pleckstrin homology domains of pleckstrin, RAC-protein kinase, diacylglycerol kinase and a new 130 kDa protein. Biochem Biophys Acta 1997; 1359 (3): 275–285.PubMedCrossRefGoogle Scholar
  48. 48.
    Didichenko SA, Tilton B, Hemmings BA, et al. Constitutive activation of protein kinase B am ‘hosphorylation of p47phox by a membrane-targeted phosphoinositide 3-kinase. Curr Biol 1996; 6(10) 71–1278.Google Scholar
  49. 49.
    Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res 1998; 152: 341–352.PubMedCrossRefGoogle Scholar
  50. 50.
    Jones A, Harris AL. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J Sci Am 1998; 4: 209–271.PubMedGoogle Scholar
  51. 51.
    Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce: Acquired drug resistance. Nature (Lond) 1997; 390: 404–407.CrossRefGoogle Scholar
  52. 52.
    Brooks PC Stromblad S, Klemke R, et al. Antiintegrin alpha v Beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Investig 1995; 96 (4): 1815–1822.PubMedCrossRefGoogle Scholar
  53. 53.
    Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond) 1993; 362: 841–844.CrossRefGoogle Scholar
  54. 54.
    Teicher BA, Sotmayor EA, Huang ZD, et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52: 6702–6704.PubMedGoogle Scholar
  55. 55.
    Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920–925.PubMedCrossRefGoogle Scholar
  56. 56.
    Lund EL, Bastholm L, Kristjansen PE, et al. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000; 6: 971–978.PubMedGoogle Scholar
  57. 57.
    Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001; 49 (2): 443–450.PubMedCrossRefGoogle Scholar
  58. 58.
    O’Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–328.PubMedCrossRefGoogle Scholar
  59. 59.
    O’Reilly M, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.PubMedCrossRefGoogle Scholar
  60. 60.
    Salloum R, Jaskowiak NT, Mauceri HJ, et al. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 2000; 60 (24): 6958–6963.PubMedGoogle Scholar
  61. 61.
    Hanna NN, Seetharam S, Mauceri HJ, et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 2000; 6 (5): 287–293.PubMedGoogle Scholar
  62. 62.
    Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–1763.PubMedCrossRefGoogle Scholar
  63. 63.
    Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998; 394: 287–291.PubMedCrossRefGoogle Scholar
  64. 64.
    Staba MT, Mauceri HJ, Kufe DW, et al. Adenoviral TNF-a gene therapy and radiation damage tumor vasculature in a human malignant glioma xenografts. Gene Ther 1998; 5: 293–300.PubMedCrossRefGoogle Scholar
  65. 65.
    Advani S, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered Herpes Simplex Virus by ionizing radiation: a new paradigm for destruction of intractable tumors. Gene Ther 1998; 5: 160–165.PubMedCrossRefGoogle Scholar
  66. 66.
    Matsuzaki H, Tamatani M, Mitsuda N, et al. Activation of Akt kinase inhibits apoptosis and changes in Bc1–2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 1999; 73 (5): 2037–2046.PubMedGoogle Scholar
  67. 67.
    Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998; 111 (Pt 24): 3621–3631.PubMedGoogle Scholar
  68. 68.
    Takahashi T, Ueno H, Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Onco gene 1999; 18 (13): 2221–2230.CrossRefGoogle Scholar
  69. 69.
    Asahara T, Masuda H, Takahasi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Res 1999; 85: 221–228.PubMedCrossRefGoogle Scholar
  70. 70.
    Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–967.PubMedCrossRefGoogle Scholar
  71. 71.
    Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337 (22): 1584–1590.PubMedCrossRefGoogle Scholar
  72. 72.
    Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997; 386 (6624): 488–493.PubMedCrossRefGoogle Scholar
  73. 73.
    Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk1-deficient mice. Nature 1995; 376 (6535): 62–66.PubMedCrossRefGoogle Scholar
  74. 74.
    Ziegler-Heitbrock HW, Sternsdorf T, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 1993; 151: 6986–6993.PubMedGoogle Scholar
  75. 75.
    Jahroudi N, Ardekani AM, Greenberger JS, et al. Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 1996; 88: 3801–3814.PubMedGoogle Scholar
  76. 76.
    Hallahan DE, Chen AY, Teng M, et al. Drug-radiation interactions in tumor blood vessels. Oncology (Huntingt) 1999; 13 (10 Suppl 5): 71–77.Google Scholar
  77. 77.
    Verheij M, Dewit LG, Bloomgaard MN, et al. Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat Res 1994; 137: 202–207.PubMedCrossRefGoogle Scholar
  78. 78.
    Old LD. Tumor necrosis factor. Science 1985; 230: 630–636.PubMedCrossRefGoogle Scholar
  79. 79.
    Mauceri HJ, Hanna NN, Wayne JD, et al. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996; 56: 4311–4314.PubMedGoogle Scholar
  80. 80.
    Donnelly EF, Geng L, Wojcicki WE, et al. Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 2001; 219: 166–170.PubMedGoogle Scholar
  81. 81.
    Sharma A, Mani S, Hanna NN, et al. An open-label, phase 1, dose-escalation study of tumor necrosis factor-alpha gene transfer (TNFerade) with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 2001; 12 (9): 1109–1131.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Dennis E. Hallahan
  • Don Stacy

There are no affiliations available

Personalised recommendations